

Content available at: <https://www.ipinnovative.com/open-access-journals>

International Journal of Recent Innovations in Medicine and Clinical Research

Journal homepage: <https://www.ijrimcr.com/>

## Review Article

# Nanotechnology in medicine: A comprehensive review of its role in modern drug delivery systems

Supriya Gandotra<sup>1</sup>, Medha Shukla<sup>2</sup>, Preeti Kale<sup>3\*</sup>

<sup>1</sup>Dept. of Anesthesia and Critical Care, Govt. Medical College, Jammu, Jammu and Kashmir, India

<sup>2</sup>All India Institute of Medical Sciences, Jammu, Jammu and Kashmir, India

<sup>3</sup>Dept. of Periodontology, Rural Dental College, PIMS(DU), Loni, Maharashtra, India



## ARTICLE INFO

### Article history:

Received 15-08-2024

Accepted 24-09-2024

Available online 11-11-2024

### Keywords:

Nanomedicine

Nanoparticles

Personalized medicine

Targeted drug delivery

## ABSTRACT

Nanotechnology has revolutionized the field of medicine, particularly in the development of modern drug delivery systems. This review provides a comprehensive exploration of the role that nanotechnology plays in enhancing drug delivery mechanisms, targeting specific sites and minimizing side effects. Advances in nanoparticle-based drug carriers, including liposomes, dendrimers and polymeric nanoparticles, offer superior bioavailability, sustained release and improved solubility for various therapeutic agents. The review delves into the latest innovations in nanocarriers, their applications in cancer treatment, gene therapy and infectious diseases and discusses the challenges of clinical translation. Furthermore, it addresses the regulatory, ethical and safety concerns surrounding nanomedicine. By highlighting both the promises and limitations of nanotechnology in drug delivery, this article aims to provide a balanced perspective on its transformative potential in modern healthcare.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Nanotechnology, the science of manipulating materials at the atomic and molecular scale (typically between 1 and 100 nanometers), has emerged as a transformative force in medicine. Due to the unique physical, chemical and biological properties exhibited by materials at the nanoscale, nanotechnology offers unprecedented opportunities for improving healthcare. Its applications span drug delivery, diagnostics, imaging and even regenerative medicine.<sup>1</sup> In drug delivery, nanotechnology enables the development of nanocarriers such as liposomes, polymeric nanoparticles and dendrimers that can encapsulate therapeutic agents, improve their stability and deliver them directly to targeted tissues. This targeted approach not only enhances treatment efficacy but also reduces

side effects, particularly in cancer therapy. Additionally, nanotechnology facilitates the creation of novel imaging agents and diagnostic tools, improving early detection and monitoring of diseases.<sup>2</sup> The field also holds promise for personalized medicine, where nanomedicine can be tailored to the individual patient's needs, offering more precise and effective treatments. As research and innovation in nanomedicine continue to advance, the integration of nanotechnology into medical practice is set to reshape modern healthcare, offering new solutions to previously intractable medical challenges.<sup>3</sup>

### 1.1. Fundamentals of drug delivery systems

Drug delivery systems are technologies designed to deliver therapeutic agents to the body in a controlled, targeted and efficient manner. Their goal is to enhance the effectiveness of drugs by optimizing their release,

\* Corresponding author.

E-mail address: [Preetikale20jan@gmail.com](mailto:Preetikale20jan@gmail.com) (P. Kale).

distribution and absorption, while minimizing side effects. Traditional drug delivery methods, such as oral or intravenous administration, often face challenges like poor bioavailability, rapid degradation of drugs and non-specific distribution, leading to potential harm to healthy tissues.<sup>4</sup> Modern drug delivery systems, particularly those using nanotechnology, address these issues by enabling:

**Controlled Release:** They regulate the rate at which a drug is released into the bloodstream, maintaining therapeutic levels over extended periods, reducing dosing frequency.

**Targeted Delivery:** Advanced systems can deliver drugs directly to specific cells or tissues (e.g., cancer cells), enhancing efficacy and reducing damage to healthy tissues.

**Improved Solubility and Stability:** Nanocarriers like liposomes, dendrimers and polymeric nanoparticles can encapsulate drugs, improving their solubility, protecting them from degradation and enhancing bioavailability.<sup>5</sup>

### 1.2. Types of nano carriers

Nano carriers are Nano scale vehicles used for the delivery of drugs, offering enhanced targeting, controlled release and improved bioavailability. Here are the main types:

**Liposomes:** Spherical vesicles made of phospholipid bilayers, liposomes encapsulate both hydrophilic and hydrophobic drugs, protecting them from degradation and delivering them to target sites, commonly used in cancer therapy.<sup>6</sup>

**Dendrimers:** Branched, tree-like macromolecules with a highly organized structure. Dendrimers have a large surface area for attaching drugs, making them ideal for carrying multiple therapeutic agents or targeting ligands.

**Polymeric Nanoparticles:** Biodegradable nanoparticles made from polymers like PLGA (polylactic-co-glycolic acid). These are used for controlled drug release and are biocompatible, making them suitable for sustained-release therapies.<sup>7</sup>

**Inorganic Nanoparticles:** Made from metals (e.g., gold, silver) or metal oxides (e.g., iron oxide), these nanoparticles are often used for imaging and drug delivery. Gold nanoparticles are used in cancer therapy for targeted delivery and photothermal treatments.

**Carbon-based Nanomaterials:** Including fullerenes, carbon nanotubes and graphene, these materials have unique physical and chemical properties, making them useful in drug delivery, diagnostics and tissue engineering.<sup>8</sup>

### 1.3. Nanotechnology and personalized medicine

Nanotechnology plays a key role in advancing personalized medicine, which tailors medical treatments to the unique genetic, molecular and environmental factors of individual patients. By using nanoscale materials, doctors can achieve more precise diagnoses and deliver highly targeted

therapies, improving the effectiveness and minimizing side effects of treatments.<sup>9</sup> In personalized drug delivery, nanocarriers (such as liposomes or nanoparticles) can be designed to target specific cells or tissues, allowing for customized dosing based on the patient's condition. This is especially beneficial in cancer therapy, where nanomedicine can deliver drugs directly to tumors while sparing healthy cells. Nanotechnology also enhances diagnostics through tools like quantum dots and nanobiosensors, which provide real-time, highly sensitive data about a patient's disease markers. This enables early detection and continuous monitoring, crucial for creating individualized treatment plans. By integrating nanotechnology, personalized medicine can offer precise, tailored therapies that improve patient outcomes and pave the way for more effective, individualized healthcare.

### 1.4. Safety and toxicological concerns

While nanotechnology offers immense potential in medicine, it also raises important safety and toxicological concerns. The small size and high reactivity of nanoparticles allow them to interact with biological systems in ways that may lead to unintended effects.<sup>10</sup>

**Nanotoxicity:** Nanoparticles can penetrate cells and tissues easily, potentially causing toxicity by generating reactive oxygen species (ROS), inducing inflammation, or damaging DNA. This can lead to adverse effects such as cell death or long-term health risks like cancer.

**Bioaccumulation and Biodistribution:** Nanoparticles may accumulate in organs like the liver, kidneys, or spleen, potentially leading to toxicity if not properly cleared from the body.

**Immunogenicity:** Some nanoparticles can trigger immune responses, leading to allergic reactions or immune system dysfunction.

**Regulatory Challenges:** The lack of standardized testing for nanoparticle safety and long-term effects complicates regulatory approval. Ensuring thorough risk assessment and safety protocols is critical before clinical use.<sup>11,12</sup>

### 1.5. Regulatory and ethical issues

Current regulations may not fully account for the unique properties of nanoparticles, making it difficult to establish standardized safety and efficacy guidelines. Regulatory bodies like the FDA and EMA are still adapting to assess the risks and benefits of nanomedicines, which may require new testing protocols for approval. The potential for unknown long-term effects of nanoparticles poses a regulatory challenge.<sup>11</sup> The lack of extensive data on nanoparticle toxicity and environmental impact complicates the approval process for new therapies. Ethical concerns arise around patient safety, informed consent and the potential for inequities in access to advanced nanomedicine

treatments. Additionally, the use of nanotechnology in genetic and personalized medicine raises questions about privacy, as it may involve extensive genetic and health data collection. Bridging the gap between laboratory research and clinical application is challenging, as scaling up nanoparticle production for widespread use must meet rigorous safety and ethical standards.<sup>13</sup>

### 1.6. Challenges

Developing scalable, reproducible methods for synthesizing nanoparticles while maintaining consistent quality can be complex and costly. As discussed, the long-term effects and potential toxicity of nanoparticles remain largely unexplored, necessitating more comprehensive studies.<sup>12</sup> Existing regulatory frameworks may not adequately address the unique properties of nanomaterials, leading to delays in approval processes for new therapies. Concerns about safety, environmental impact and ethical implications can influence public acceptance of nanomedicine, requiring effective communication and transparency.<sup>14</sup>

## 2. Future directions

Research is advancing toward developing intelligent nanoparticles that respond to specific stimuli (e.g., pH, temperature) to release drugs in a controlled manner. Exploring the use of nanocarriers to simultaneously deliver multiple therapeutic agents can enhance treatment efficacy, particularly in complex diseases like cancer.<sup>15</sup> Leveraging patient-specific data (genomic and proteomic) to create tailored nanomedicine approaches could lead to more effective and individualized therapies. The application of artificial intelligence in nanotechnology research can accelerate drug discovery, optimize nanoparticle design and improve treatment personalization.<sup>16</sup>

## 3. Discussion

Nanotechnology's application in medicine presents both remarkable opportunities and significant challenges. Its ability to enhance drug delivery through targeted, controlled and sustained release systems revolutionizes treatment approaches, particularly in oncology and chronic diseases. However, concerns regarding safety, toxicity and regulatory oversight must be rigorously addressed to ensure patient safety and efficacy. Future research should focus on developing smart nanocarriers, exploring combination therapies and leveraging artificial intelligence to optimize treatment protocols. Collaborative efforts among researchers, clinicians, regulatory bodies and the public will be crucial in navigating the complexities of nanomedicine and realizing its full potential in transforming healthcare.<sup>17</sup>

## 4. Conclusion

Nanotechnology holds transformative potential in medicine, enhancing drug delivery, diagnostics and personalized treatments. While challenges related to safety, regulation and public perception remain, ongoing research and innovation will drive the integration of nanotechnology into healthcare, paving the way for more effective and individualized medical solutions.

## 5. Source of Funding

None.

## 6. Conflict of Interest

None.


## References

1. Sim S, Wong NK. 2021.
2. Belkin A, Hubler A, Bezryadin A. Self-assembled wiggling nanostructures and the principle of maximum entropy production. *Sci Rep*. 2015;5(8323):8323.
3. Mashaghi S, Jadidi T, Koenderink G, Mashaghi A. Lipid nanotechnology. *Int J Mol Sci*. 2013;14(2):4242–82.
4. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. *Adv Drug Deliv Rev*. 2006;58(14):1456–9.
5. Lombardo D, Kiselev MA, Caccamo MT. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. *J Nanomaterials*. 2019;2019:1–26.
6. Morgan MT, Carnahan MA, Finkelstein S, Prata CA, Degoricija L, Lee SJ, et al. Dendritic supramolecular assemblies for drug delivery. *Chem Commun*. 2005;34:4309–11.
7. Helm L. Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications. *Future Med Chem*. 2010;2(3):385–96.
8. Ocheke NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part I: Background and applications. *Trop J Pharm Res*. 2009;8:265–74.
9. Jain N, Jain R, Thakur N, Gupta BP, Jain DK, Banveer J, et al. Nanotechnology: A Safe and effective drug delivery system. *Asian J Pharm Clin Res*. 2010;3(2):159–65.
10. Najlah M, Freeman S, Attwood D, D'Emanuele A, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. *Int J Pharm*. 2007;336(1):183–90.
11. Nie L, Liu F, Ma P, Xiao X. Applications of gold nanoparticles in optical biosensors. *J Biomed Nanotechnol*. 2014;10(10):2700–21.
12. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomater*. 2005;26(18):3995–4021.
13. Cole LE, Ross RD, Tilley JM, Gogola TV, Roeder RK. Gold nanoparticles as contrast agents in x-ray imaging and computed tomography. *Nanomedicine (Lond)*. 2015;10(2):321–41.
14. Singh P. Impacts of nanotechnology on environmental (Review). *Int Arch App Sci Technol*. 2018;9(3):14–16.
15. Dreher KL. Health and environmental impact of nanotechnology: Toxicological assessment of manufactured nanoparticles. *Toxicol Sci*. 2004;77(1):3–5.
16. Stander L, Theodore L. Environmental implications of nanotechnology - an update. *Int J Environ Res Public Health*. 2011;8(2):470–9.
17. Babatunde DE, Denwigwe IH, Babatunde OM, Gbadamosi SL, Babalola IP, Agboola O. Environmental and Societal Impact of. *IEEE Access*. 2020;8:4640–67.

### Author's biography

**Supriya Gandotra**, Senior Resident

**Medha Shukla**, Senior Resident

**Preeti Kale**, Lecturer  <https://orcid.org/0000-0003-3753-4105>

**Cite this article:** Gandotra S, Shukla M, Kale P. Nanotechnology in medicine: A comprehensive review of its role in modern drug delivery systems. *Int J Recent Innov Med Clin Res* 2024;6(4):108-111.